Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Titel:
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Auteur:
Eggermont, Alexander M M Chiarion-Sileni, Vanna Grob, Jean-Jacques Dummer, Reinhard Wolchok, Jedd D Schmidt, Henrik Hamid, Omid Robert, Caroline Ascierto, Paolo A Richards, Jon M Lebbé, Céleste Ferraresi, Virginia Smylie, Michael Weber, Jeffrey S Maio, Michele Konto, Cyril Hoos, Axel de Pril, Veerle Gurunath, Ravichandra Karra de Schaetzen, Gaetan Suciu, Stefan Testori, Alessandro